NOTE

🌱 created from: palliative_intent-of-hnscc

checkmate_141

The CheckMate 141 study showed that nivolumab treatment resulted in longer overall survival (7.5 months) compared to standard, single-agent therapy (5.1 months) in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, with a response rate of 13.3% vs. 5.8% and a lower rate of treatment-related adverse events of grade 3 or 4 (13.1% vs. 35.1%).

1.Ferris RL. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine. Published November 10, 2016. Accessed September 28, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa1602252